# Oncimmune Holdings plc strong progress in three year forward strategy

- Link: https://www.directorstalkinterviews.com/oncimmune-holdings-plc-strong-progress-in-three-year-forward-strategy/412796743
- Published: 2019-10-31T07:08:23+00:00
- Author: Giles Arbor

**Oncimmune Holdings plc** (LON: ONC), the leading global immunodiagnostics group,
today announced its preliminary unaudited full year results for the year ended 31
May 2019. The audited full year results are expected to be available shortly.

**Corporate & Operational Highlights (including post-period end)**

 * Publication of positive top line results of the Early detection of Cancer of 
   the Lung Scotland (“ECLS”) trial with 12,209 patients, believed to be the largest
   randomised controlled study using blood biomarkers for the detection of lung 
   cancer
 * Initiation of multi-centre trial of EarlyCDT Lung with Genostics Company Limited
   in China which will study approximately 1,000 early lung cancers at five leading
   academic health centres
 * Gene Group puts in place plan to provide EarlyCDT Lung tests for screening and
   nodules from Hainan, China ahead of local regulatory approval
 * Minimum sales commitments valued at £42m1 over a period of five years with 19
   separate distributors across the world (2018: £29m)
 * Acquisition of Protagen Diagnostics AG provides additional revenue source through
   service partnerships with pharmaceutical companies
 * Agreements signed by Vithas Group and Quirónsalud Group, two of Spain’s largest
   private hospital groups to distribute EarlyCDT Lung as nodule and screening test
 * Strategic commercial agreements signed in July 2019 with Biodesix Inc. in the
   US valued at up to $28m2 over the next five years, and continued partnership 
   beyond this date.
 * Commercial partnership agreement signed with R-Pharm in July 2019 valued at £
   5m; R-Pharm to invest up to £3.5m in screening infrastructure in Russia
 * Appointment of key new Senior Leadership Team members including Matthew Hall,
   Andrew Stewart, Tariq Sethi and Matt Luttrell to add further capabilities to 
   management

**Unaudited Financial Highlights (including post-period end)**

 * Revenue for the year £171k (2018: £240k)
 * R&D costs for the year were £1.5m (2018: £800k)
 * Net loss for the year was £8.0m (2018: £6.3m)
 * Cash balance at the period end of £5.4m (2018: £12.95m)
 * Post-period end, the Company secured a €8.5m debt facility in September 2019

**Dr Adam Hill, CEO of Oncimmune Holdings commented: **

> “We are delighted with the strong progress made in rolling out our three year 
> forward strategy over the last 12 months. We have made important advancements 
> in the commercial and clinical development of the Company, including the acquisition
> of Protagen, strategic partnership with Biodesix, and the presentation of positive
> data from the ECLS study. The potential for the forthcoming commercial Cancer 
> Control Evaluation in the UK, along with the forward-looking product sales commitments
> of £42m and a strengthening pipeline of service revenue, gives us confidence in
> our platform and the potential to generate material revenues in 2020 and beyond.”

Share on:
